- Home
- IFRX vs RENE Comparison
IFRX vs RENE Comparison
Compare IFRX & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- RENE
- Stock Information
- Founded
- IFRX 2007
- RENE 2021
- Country
- IFRX Germany
- RENE United States
- Employees
- IFRX N/A
- RENE N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- RENE Blank Checks
- Sector
- IFRX Health Care
- RENE Finance
- Exchange
- IFRX Nasdaq
- RENE Nasdaq
- Market Cap
- IFRX 143.7M
- RENE 151.4M
- IPO Year
- IFRX 2017
- RENE 2022
- Fundamental
- Price
- IFRX $2.47
- RENE $11.71
- Analyst Decision
- IFRX Strong Buy
- RENE
- Analyst Count
- IFRX 1
- RENE 0
- Target Price
- IFRX $8.00
- RENE N/A
- AVG Volume (30 Days)
- IFRX 174.5K
- RENE 4.1K
- Earning Date
- IFRX 11-08-2024
- RENE 01-01-0001
- Dividend Yield
- IFRX N/A
- RENE N/A
- EPS Growth
- IFRX N/A
- RENE 42.92
- EPS
- IFRX N/A
- RENE 0.43
- Revenue
- IFRX $187,930.00
- RENE N/A
- Revenue This Year
- IFRX $392.79
- RENE N/A
- Revenue Next Year
- IFRX $156.76
- RENE N/A
- P/E Ratio
- IFRX N/A
- RENE $26.90
- Revenue Growth
- IFRX 177.12
- RENE N/A
- 52 Week Low
- IFRX $1.17
- RENE $11.01
- 52 Week High
- IFRX $2.82
- RENE $11.78
- Technical
- Relative Strength Index (RSI)
- IFRX 53.59
- RENE 56.27
- Support Level
- IFRX $2.16
- RENE $11.56
- Resistance Level
- IFRX $2.65
- RENE $11.70
- Average True Range (ATR)
- IFRX 0.23
- RENE 0.02
- MACD
- IFRX -0.01
- RENE -0.00
- Stochastic Oscillator
- IFRX 52.54
- RENE 68.18
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.